HOME PREV
|
|
|
|
|
|
|
|
|
| Schering's Peg-Intron plus Rebetol | ||||||||
| SVR for Peg-Intron plus Rebetol combination therapy is 42% for genotype 1 (30% for high viral load)and 82%for genotypes 2 and 3.Treatment duration for all genotypes is 12 months. | ||||||||
| Roche's Pegasys plus Copegus | ||||||||
| SVR for Pegasys plus Copegus combination therapy is 46 -51% for genotype 1 (41 -46% for high viral load)and 76 -78% for genotypes 2 and 3.Treatment duration is 12 months for genotype 1,and 6 months for genotypes 2 and 3. Measuring Treatment Response People receiving HCV treatment should be tested on a regular basis to monitor side effects and to make sure that they are responding to therapy.If someone has not responded after three months of treatment,further therapy is unlikely to clear the virus. Many physicians recommend stopping the medications at this time. However,some evidence suggests that interferon can decrease scarring and inflammation and improve liver health even if it does not clear the virus. Virological Response how a person's viral load level responds to treatment.When a person's HCV RNA (viral load)becomes undetectable after HCV therapy has been initiated,this is considered a virological response. If the HCV RNA remains undetectable beyond six months,the term sustained virological response (SVR)is used. | ||||||||
| (Source of the Article: HCV advocate August 2003) HOME PREV |
||||||||